Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 5/20 | 0.46 |
| ▸ | CD74 | P04233 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16412436 | 1.00 | MIF (0.46) | MIFCD74HRH3POLBPPARG | |
| SCHEMBL16412405 | 0.96 | HRH3 (0.42) | MIFCD74HRH3POLBMAPT | |
| SCHEMBL16412403 | 0.96 | HRH3 (0.42) | MIFCD74HRH3POLBMAPT | |
| SCHEMBL16419244 | 0.91 | MIF (0.45) | MIFCD74POLBMAPTSIGMAR1 | |
| SCHEMBL16413401 | 0.87 | MIF (0.50) | MIFCD74POLBMAPTSIGMAR1 | |
| SCHEMBL16413402 | 0.87 | MIF (0.50) | MIFCD74POLBMAPTSIGMAR1 | |
| SCHEMBL16412979 | 0.86 | OPRK1 (0.48) | MIFCD74POLBMAPT | |
| SCHEMBL16412977 | 0.85 | MAPT (0.40) | MIFCD74POLBMAPT | |
| SCHEMBL16412980 | 0.85 | MAPT (0.40) | MIFCD74POLBMAPT | |
| SCHEMBL16413040 | 0.84 | MIF (0.44) | MIFCD74POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131655-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | DR. REDDY'S LABORATORIES, LTD. (IN) | 2018-11-20 | — | — | US | claimed |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | DR. REDDY'S LABORATORIES, LTD. (IN) | 2017-01-05 | — | — | US | claimed |
| US-20150031685-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | Dr. Reeddy's Laboratories Ltd. (IN) | 2015-01-29 | — | — | US | claimed |
| US-10131655-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | DR. REDDY'S LABORATORIES, LTD. (IN) | 2018-11-20 | — | — | US | disclosed |
| EP-2822928-B1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | Dr Reddys Laboratories Ltd (IN) | 2018-11-14 | — | — | EP | disclosed |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | DR. REDDY'S LABORATORIES, LTD. (IN) | 2017-01-05 | — | — | US | disclosed |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | DR. REDDY'S LABORATORIES, LTD. (IN) | 2017-01-05 | — | — | US | disclosed |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | DR. REDDY'S LABORATORIES, LTD. (IN) | 2017-01-05 | — | — | US | disclosed |
| US-9487510-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-11-08 | — | — | US | disclosed |
| US-20150031685-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | Dr. Reeddy's Laboratories Ltd. (IN) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031685-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | OPRK1, OPRL1, OPRD1 | MIF 3417/4885CD74 4409/4885HRH3 68/4885 |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | OPRK1, OPRL1, OPRD1 | MIF 3441/4885CD74 4421/4885HRH3 65/4885 |
| US-10131655-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | OPRK1, OPRL1, OPRD1 | MIF 3441/4885CD74 4421/4885HRH3 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.